Skip to content

Free shipping on all £45+ orders


We are Cannabotech. We’re a biomedical company that mixes nature and science to supercharge treatments for today’s most pressing health issues. You might say we’re something of a botanical pharmacy. As one of the first biomedical companies to marry traditional Asian expertise with modern science, we have harnessed the (often untapped) benefits of cannabinoids and medicinal mushrooms and, in doing so, we have created our proprietary and patent-pending formula: M²CBD.

  • Dr Dov Melamed

    Dov Melamed is a research scientist with over 15 years of experience in Biopharma. Most notable, he was a researcher at Bar Ilan's Male Fertility Clinic and QBI. He completed his Ph.D. in Biotechnology at Bar-Ilan University.

  • Dr Basem Fares

    Basam Fares received his Ph.D. in Oncology and Cancer Biology from the Faculty of Medicine in the Technion Institute of Technology. He is a cancer researcher at the Rambam Oncology Department and a research assistant at Mount Carmel Hospital and Prolor Biotech.

  • Dr Efrat Oron

    Efrat Oron is a molecular biologist, with an MSc and PhD from Tel-Aviv University. She completed her post-doctoral research on embryonic stem cells at Yale University. She has been an associate research scientist at the University of California and a scientific advisor at the Israeli Prime Minister’s Office “Mimshak” fellow.

  • Prof. Fuad Fares

    Fuad Fares is a world-renowned biologist and pharmacologist. He is the founder & director of the Department of Molecular Genetics at Carmel Medical Center and associate professor in the Department of Human Biology at Haifa University

  • Prof. Yuval Heled

    Yuval Heled Ph.D., LLB, is a physiologist and scientist. He is a world-class expert in integrative physiology and physiology of effort, in the study of metabolic processes, and in disease prevention. He is a Professor at the Hebrew University of Jerusalem.

  • Prof. Haim Lutan

    Haim Lotan is a prominent world figure in cardiology. He is the director of cardiology at Hadassah University Hospital, former president of the Israel Cardiology Association, and founder of the Israeli Department of Invasive Cardiology


Quality and integrity are at the heart of everything we do – which is why we actively invest in CBD and mushroom research to ensure we’re at the forefront of science and research, putting us several steps ahead of our peers.

As such, we have our products manufactured in a facility that adheres to both the current Good Manufacturing practice (cGMP) and the standards set out by the International Organization for Standardization (ISO). 

Additionally, we adhere to the standards set by the Cosmetic, Toiletry, and Perfumery Association (CTPA), and by the Medicines and the Food Standards Agency (FSA) — as well as all necessary EU regulations.

Our products contain only CBD isolate (or ‘pure CBD’), and we comply with local laws for CBD hemp extract – which dictate that legal CBD can only contain trace amounts of THC up to 0.2%. THC is the intoxicating, psychoactive cannabinoid of the hemp plant. 


Our PhD research scientists, medical doctors, professors, pharmacists and nutritional therapists are on a mission to put effective, preventative care solutions into the hands of the consumer – helping them take a proactive approach to protecting their health. 

With a total of over 150 years’ experience in fields such as medicine, academia, research, medical and pharmaceutical development, education, global management and retail, Cannabotech’s leadership and scientific team are united in one common mission: to create, hone and deploy the next generation of preventative care to improve the health of millions of people across the globe.

Mixing cutting-edge science with botanical innovations, our team also make biomedical breakthroughs, the waves of which are felt worldwide. One such example is our ongoing development of a botanical drug targeting both pancreatic and colorectal cancer cells. In our recent studies, it has been shown to kill 100% of pancreatic cancer cells. 

We’re also close to launching a wide range of integrative oncology products to oncologists and hospitals in California, USA. This integrative oncology product is made up of 13 different cannabinoids and specific medicinal mushrooms, extracted with precision using a multitude of methods. The product will work in tandem with traditional chemotherapy to help reduce cancer cell viability in eight different types of cancer, aiding in the reduction of tumour size while having fewer side effects than a traditional course of chemotherapy. Learn more about our integrative oncology work here. 

Follow us on social media for updates on our preventative care products, our botanical drug development and our integrative oncology products: